Nephrogenic Systemic Fibrosis and Class Labeling of Gadolinium-based Contrast Agents by the Food and Drug Administration

作者：Lucie L. Yang, Ira Krefting, Alex Gorovets, Louis Marzella, James M. Kaiser, Robert J. Boucher, Dwaine Rieves · 发表于：Radiology · 年份：2012 · DOI：10.1148/radiol.12112783 · 被引用次数：117 · 研究领域：Lanthanide and Transition Metal Complexes、Luminescence Properties of Advanced Materials、Radioactive element chemistry and processing

In 2007, the Food and Drug Administration requested that manufacturers of all approved gadolinium-based contrast agents (GBCAs), drugs widely used in magnetic resonance imaging, use nearly identical text in their product labeling to describe the risk of nephrogenic systemic fibrosis (NSF). Accumulating information about NSF risks led to revision of the labeling text for all of these drugs in 2010. The present report summarizes the basis and purpose of this class-labeling approach and describes some of the related challenges, given the evolutionary nature of the NSF risk evidence. The class-labeling approach for presentation of product risk is designed to decrease the occurrence of NSF and to enhance the safe use of GBCAs in radiologic practice.